Therapy resistance is a substantial problem in cancer therapy and much effort has been made to overcome it. Resistance is not developed due to a single molecular change, but rather due to a series of events, which are not the same in different cancer types, which makes overcoming this issue even more challenging. Although multidrug-resistant efflux pumps are generally thought to be the major resistance mechanism, numerous subtle changes working together could be also involved.
The subtle changes underlying the multidrug resistance phenomenon are metabolic plasticity, boosts of the antioxidant system during adaptation to oxidative stress, changes in proteasomes and endoplasmic reticulum function, and changes in mitochondria. As stated, multidrug resistance to cancer cannot be attributed to a single protein or protein family, but rather involves a series of events affecting several cellular processes at the same time. Therefore, this is the main obstacle in finding appropriate cancer therapies and a problem that researchers have not yet managed to solve.
This Research Topic aims to provide an overview of cellular processes, as well as specific mechanisms and proteins, which are modified under therapy, leading to cancer adaptation to stress. The processes and molecules affected in multidrug resistance include, but are not limited to, ABC efflux transporters, mitochondrial changes, adaptation to oxidative stress, and Nrf2. We welcome submissions which cover a wide range of changes in cellular processes which lead to tumor resistance in the form of original research articles or review articles providing novel insights. Areas to be covered in this Research Topic may include, but are not limited to:
• ABC efflux transporters
• Adaptation to oxidative stress
• Antioxidative defense system
• DNA repair
• Autophagy
• Apoptosis
• Adaptation to endoplasmic stress
• Cancer stem cells
• Drug-tolerant cells
• Cancer metabolism
• Tumor-microenvironment interactions
• Inflammation
Therapy resistance is a substantial problem in cancer therapy and much effort has been made to overcome it. Resistance is not developed due to a single molecular change, but rather due to a series of events, which are not the same in different cancer types, which makes overcoming this issue even more challenging. Although multidrug-resistant efflux pumps are generally thought to be the major resistance mechanism, numerous subtle changes working together could be also involved.
The subtle changes underlying the multidrug resistance phenomenon are metabolic plasticity, boosts of the antioxidant system during adaptation to oxidative stress, changes in proteasomes and endoplasmic reticulum function, and changes in mitochondria. As stated, multidrug resistance to cancer cannot be attributed to a single protein or protein family, but rather involves a series of events affecting several cellular processes at the same time. Therefore, this is the main obstacle in finding appropriate cancer therapies and a problem that researchers have not yet managed to solve.
This Research Topic aims to provide an overview of cellular processes, as well as specific mechanisms and proteins, which are modified under therapy, leading to cancer adaptation to stress. The processes and molecules affected in multidrug resistance include, but are not limited to, ABC efflux transporters, mitochondrial changes, adaptation to oxidative stress, and Nrf2. We welcome submissions which cover a wide range of changes in cellular processes which lead to tumor resistance in the form of original research articles or review articles providing novel insights. Areas to be covered in this Research Topic may include, but are not limited to:
• ABC efflux transporters
• Adaptation to oxidative stress
• Antioxidative defense system
• DNA repair
• Autophagy
• Apoptosis
• Adaptation to endoplasmic stress
• Cancer stem cells
• Drug-tolerant cells
• Cancer metabolism
• Tumor-microenvironment interactions
• Inflammation
